Asdar Group -- New Board Member Appointed.Business Editors VANCOUVER, British Columbia--(BUSINESS WIRE)--Jan. 22, 2002 Asdar Group (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :XBET) announces the appointment of Dr. Hai Shiene Chen M.D., M.Sc. to the Board of Directors. Dr. Chen was educated at the Second Military Medical University in Shanghai, China and received his medical degree in 1983 graduating in the top two percent of his class. From 1986 to 1988, Dr. Chen trained in cancer research at the Harvard Medical School Harvard Medical School (HMS) is one of the graduate schools of Harvard University. It is a prestigious American medical school located in the Longwood Medical Area of the Mission Hill neighborhood of Boston, Massachusetts. . In 1990, Dr. Chen obtained a M.Sc. in genetics from the University of Toronto Research at the University of Toronto has been responsible for the world's first electronic heart pacemaker, artificial larynx, single-lung transplant, nerve transplant, artificial pancreas, chemical laser, G-suit, the first practical electron microscope, the first cloning of T-cells, and while there directed a research project on HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. . From 1991 to 1996, Dr. Chen was Managing Director of the Canadian Genetic Diseases Network Core Facility. In 1995, Dr. Chen founded ACGT Corporation and currently acts as its President and C.E.O. Asdar has the right to purchase 31.6% of ACGT Corporation, a Toronto based Biotech Company with three divisions including, DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. Services, DNA Diagnostics and Gene Therapy. The Company is currently establishing an Advisory Board, which will include experienced individuals in the field of biotechnology. Ferdinand Marehard has resigned as a Director and Officer of the Company, effective immediately. /s/ Robert Waters Robert Waters M.B.A., President For further information please contact Joseph Beyrouti Investor Relations at: 888/488-6882 Safe Harbor Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: The statements contained herein which are not historical fact are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but no limited to, certain delays in testing and evaluation of products and other risks detailed from time to time in Asdar's filings with the Securities & Exchange Commission. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion